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To transfuse or not to transfuse: that is the question! 
And this is a longstanding issue that has to be faced if we 
want to consider allogeneic blood transfusion to be a life-
saving procedure. It does, however, involve several risks, 
including infectious (viral and bacterial) complications, 
transfusion-related acute lung injury, ABO- and non-
ABO-associated haemolytic transfusion reactions, 
transfusion-associated Graft-versus-Host disease, 
and transfusion-associated circulatory overload1. 
These complications represent the principal causes 
of allogeneic blood transfusion-related morbidity and 
mortality. Over the last thirty years, this has led to a 
number of randomised controlled trials (RCTs) being 
carried out aimed at comparing the effect on patients of 
restrictive (haemoglobin concentration 7-8 g/dL) with 
more liberal (haemoglobin concentration approximately 
10 g/dL) blood transfusion strategies in a variety of 
clinical settings2. In parallel, a number of systematic 
reviews and meta-analyses3-10 have been conducted with 
the aim of performing a pooled analysis of the data from 
these RCTs (see Table I for a summary of results). 
A systematic review of papers published up to 2000 
identified 10 trials, and the investigators concluded that 
the evidence supported the use of restrictive transfusion 
triggers in patients without serious cardiac disease3. A 
2012 Cochrane systematic review, including 19 trials 
with 6,264 patients, showed that patients receiving liberal 
transfusion had higher in-hospital mortality compared 
with those transfused with a restrictive strategy4. A 2014 
meta-analysis and systematic review by Salpeter et al. 
focused on the question as to whether the lower 7 g/dL 
threshold is superior to the higher threshold of 8 g/dL. 
Their study showed that, in patients with critical illness 
or bleeding, restricting blood transfusions by using a 
haemoglobin trigger lower than 7 g/dL significantly 
reduces negative outcomes, as well as in-hospital and 
total mortality6.
A more recent systematic review and meta-analysis 
of 31 RCTs by Holst et al. revealed a reduction in 
the number of units and of patients transfused in the 
restrictive group compared with the liberal group, but 
there was no difference in mortality and morbidity7. 
From the overall analysis of these systematic reviews 
(Table I), it is clear that, in terms of morbidity and 
mortality, a restrictive red blood cell (RBC) transfusion 
approach is superior3,4,6 or equivalent5,7-9 to a liberal 
strategy. 
Recently, Fominskiy et al.10 performed yet another 
meta-analysis, justifying their efforts on the basis of the 
inclusion of three additional RCTs published in 2015 
that had not been included in the previous systematic 
reviews11-13. The authors claimed that their meta-
analysis, which included 27 RCTs with 11,021 patients, 
demonstrated unequivocally the superiority in terms of 
overall survival of the liberal transfusion strategy over 
the conservative approach in peri-operative adult patients 
(but not in critically ill patients). Besides a number of 
criticisms that could be raised on the selection criteria and 
data analysis, such as the inclusion of studies with a wide 
clinical heterogeneity, the overlaps between restrictive 
and non-restrictive blood transfusion thresholds, and 
the choice of the 90-day all-cause mortality as primary 
outcome (instead of the more reasonable 30-days cut-
off chosen by the majority of trials), the main weakness 
of their work lies in the statistical analysis performed. 
Indeed, in their meta-analysis the authors should have 
calculated the risk ratio (RR) rather than the odds ratio 
(OR). The pooled effect size measured by the RR is 
a more appropriate tool for a meta-analysis aimed at 
evaluating the efficacy of a treatment protocol (liberal vs. 
restrictive transfusion approach) in preventing an adverse 
event (90-day all-cause mortality). This is corroborated 
by the fact that all previous meta-analyses published on 
this topic used an RR-based meta-analytical approach. 
If we re-analyse the 17 peri-operative studies from the 
meta-analysis conducted by Fominskiy et al. using the 
RR10, the already border-line statistical significance 
regarding a lower all-cause mortality with liberal vs 
restrictive transfusion strategy observed using the OR 
(0.81, 95% CI: 0.66-1; p=0.050) disappears (RR 0.83, 
95% CI: 0.689-1.001; p=0.051) (Figure 1). Notably, 
when the same authors performed a sub-analysis of 
all included trials (i.e. peri-operative and critically ill 
patients) considering only the high-quality studies with 
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Table I - Main results of the systematic reviews and meta-analyses of trials on blood transfusion strategies in various clinical settings.
First author, year 
[reference]
Selection 
criteria
Studies/patients 
included
Main findings
Carson, 2002 [3] RCTs 1970-2001 10/1,780 The literature analysis supported the use of restrictive transfusion triggers in patients without 
serious cardiac disease.
Carson, 2012 [4] RCTs 1970-2011 19/6,264 Restrictive vs liberal transfusion strategy was associated with a statistically significant 
reduction in hospital mortality (RR 0.77, 95% CI: 0.62-0.95).
Curley, 2014 [5] RCTs 1950-2013 7/1,262 Restrictive vs liberal transfusion strategy was associated with a decreased transfusion of 
RBCs (mean difference −0.71, 95% CI: −0.31 to −1.09)  without an associated change in 
adverse events in patients undergoing cardiovascular surgery.
Salpeter, 2014 [6] RCTs 1966-2013 3/23,641 Restrictive vs liberal transfusion strategy significantly reduced cardiac events (RR 0.44; 
95% CI: 0.22-0.89), re-bleeding (RR 0.64, 95% CI: 0.45-0.90), bacterial infections (RR 
0.86; 95% CI: 0.73-1.00), in-hospital mortality (RR 0.74, 95% CI: 0.60-0.92), and total 
mortality (RR 0.80; 95% CI: 0.65-0.98).
Holst, 2015 [7] RCTs 1950-2014 31/9,813 Restrictive vs liberal transfusion strategy was associated with a decreased transfusion of 
RBCs (mean difference −1.43, 95% CI: −2.01 to −0.86) with no effect on overall morbidity 
and mortality risks.
Brunskill, 2015 [8] RCTs 1946-2014 6/2,272 No difference in mortality, functional recovery or post-operative morbidity between 
restrictive and liberal thresholds was observed.
Ripollés Melchor, 
2015 [9]
RCTs 1950-2014 6/2,156 No differences in mortality between the restrictive and liberal groups (RR 0.86, 95% CI: 
0.70-1.05; p=0.14) were observed.
Fominskiy, 2015 [10] RCTs 1986-2015 27/11,021 Liberal transfusion strategy compared with restrictive strategy improved survival in 
perioperative patients (OR 0.81, 95% CI: 0.66-1; p=0.050)
1 Only RCTs using a restrictive transfusion trigger <7 g/dL were included. RCTs: randomised controlled trials; RR: risk ratio; CI: confidence interval; RBCs: 
red blood cells; OR: odds ratio. 
Figure 1 - Forest-plot of all-cause mortality in peri-operative patients: risk ratio calculation (data extracted 
from the meta-analysis by Fominskiy et al.10).
 Four studies did not record events and were excluded from analysis. Statistical analysis performed 
using Stata 14.1 (StataCorp, College Station, TX, USA). RR: relative risk; CI: confidence interval. 
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a low risk of bias (Online Supplementary Table II of the 
meta-analysis10),  the OR was not statistically significant 
(0.88, 95% CI: 0.75-1.04, p=0.13), thus aligning their 
results with those of previous meta-analyses. Therefore, 
we believe that the authors should have highlighted the 
limited evidence provided by their statistical analysis 
and suggested that an interpretation of their data should 
be approached with greater caution. In conclusion, it is 
our view that the meta-analysis by Fominskiy et al.10 
adds very little to the existing knowledge in this clinical 
setting. In addition, as specialists in transfusion medicine, 
we are well aware that RBC transfusion is a life-saving 
therapy not without risks14,15 and, consequently, we 
recommend, in accordance with recent international 
transfusion medicine and multidisciplinary guidelines, 
that decisions on transfusion therapy with RBCs be 
based on both the patient's haemoglobin values as well 
as symptoms of anaemia, and a restrictive transfusion 
approach be adopted with the possible exception of 
patients with severe ischaemic heart disease16-19. 
The Authors declare no conflicts of interest.
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